{"disease":{"id":"post-exposure-prophylaxis","name":"post exposure prophylaxis"},"drugs":{"marketed":[{"drug_id":"baloxavir","indication_name":"Post-exposure prophylaxis of influenza","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xofluza","generic_name":"BALOXAVIR","company_name":"Genentech Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":52,"revenue":null,"mechanism":"Xofluza works by inhibiting the endonuclease activity of the influenza virus, preventing it from replicating."},{"drug_id":"baloxavir","indication_name":"Post-Exposure Prophylaxis of Influenza","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xofluza","generic_name":"BALOXAVIR","company_name":"Genentech Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":52,"revenue":null,"mechanism":"Xofluza works by inhibiting the endonuclease activity of the influenza virus, preventing it from replicating."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05846568","title":"Study to Evaluate GR1801's Efficacy and Safety","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07330427","title":"Impact of Health Education on Knowledge, Attitude and Practice of Post-exposure Prophylaxis","phase":"NA","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"Aswan University","has_results":false},{"nct_id":"NCT07327307","title":"Real World Evidence Study of SYN023 in Children Exposed to Rabies","phase":"","overall_status":"RECRUITING","enrollment_count":232,"lead_sponsor_name":"Synermore Biologics (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT05684185","title":"Immunogenicity Assessment of Subjects Receiving Rabies Post-exposure Prophylaxis in Cambodia","phase":"","overall_status":"COMPLETED","enrollment_count":215,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT04321174","title":"COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":123,"lead_sponsor_name":"Unity Health Toronto","has_results":false},{"nct_id":"NCT07342257","title":"SYN023 With Rabies Vaccine in Healthy Pediatric Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"Synermore Biologics (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT04656522","title":"Comic Intervention for Sexual Violence Prevention and Post-rape Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"University of Toronto","has_results":false},{"nct_id":"NCT06007534","title":"Pharmacokinetic Characterization of a Single 200 mg Dose of Doxycycline in Post-exposure Prophylaxis (PEP) of Sexually Transmitted Infections in Different Biological Compartments","phase":"NA","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}